Epinephrine plays a key role in the control of vasomotor tone; however, the participation of the NO/cGMP pathway in response to ␤-adrenoceptor activation remains controversial. To evaluate the involvement of the endothelium in the vascular response to epinephrine, we assessed NO production, endothelial NO synthase phosphorylation, and tissue accumulation of cGMP in the perfused arterial mesenteric bed of rat. Epinephrine elicited a concentration-dependent increase in NO (EC50 of 45.7 pM), which was coupled to cGMP tissue accumulation. Both NO and cGMP production were blocked by either endothelium removal (saponin) or NO synthase inhibition (N -nitro-L-arginine). Blockade of ␤1-and ␤2-adrenoceptors with 1 M propranolol or ␤ 3-adrenoceptor with 10 nM SR 59230A displaced rightward the concentration-NO production curve evoked by epinephrine. Selective stimulation of ␤1-, ␤2-, or ␤3-adrenoceptors also resulted in NO and cGMP production. Propranolol (1 M) inhibited the rise in NO induced by isoproterenol or the ␤ 2-adrenoceptor agonists salbutamol, terbutaline, or fenoterol. Likewise, 10 nM SR 59230A reduced the effects of the ␤3-adrenoceptor agonists BRL 37344, CGP 12177, SR 595611A, or pindolol. The NO production induced by epinephrine and BRL 37344 was associated with the activation of the phosphatidylinositol 3-kinase/Akt pathway and phosphorylation of eNOS in serine 1177. In addition, in anaesthetized rats, bolus administration of isoproterenol, salbutamol, or BRL 37344 produced NO-dependent reductions in systolic blood pressure. These findings indicate that ␤1-, ␤2-, and ␤3-adrenoceptors are coupled to the NO/cGMP pathway, highlighting the role of the endothelium in the vasomotor action elicited by epinephrine and related ␤-adrenoceptor agonists. Most recently, the effect of NO synthase (NOS) blockers on the vasodilation induced by ␤ 1 -, ␤ 2 -, and ␤ 3 -adrenoceptors hinted that the activation of the NO/cGMP pathway may also be involved in the response to ␤-adrenoceptors (2, 8, 10, 19, 33, 35, 41) . In addition, an impaired vasodilator response to ␤-adrenoceptor agonists has been observed in cardiovascular diseases associated with endothelial dysfunction such as hypertension (6, 38), which also suggests that an endotheliumdependent component contributes to the vasomotor signaling triggered by ␤-adrenergic activity. However, the participation of the NO/cGMP pathway in the vascular response to ␤-adrenoceptor activation remains controversial. The finding that ␤ 1 -and ␤ 2 -adrenoceptors are rapidly desensitized in isolated cells and in reconstituted receptor-G s protein preparations (22, 30, 32) but not in human forearm arteries (37) led to Whalen et al. (45) to hypothesize that NO prevents the rapid desensitization of ␤-adrenoceptors in vivo. Consequently, these authors proposed that the sensitivity of the vasodilator response elicited by ␤-adrenoceptors to the NO availability simply may reflect the indirect effect of the basal NO production on the ␤-adrenoceptors expressed in the smooth muscle cells (44, 45) .
mesenteric bed, which suggests that, in vivo, the vasoconstriction caused by the release of norepinephrine from the sympathetic nerve endings is likely the result of the parallel stimulation of adrenoceptors located in the smooth muscle cells as well as in the endothelial cells.
Most recently, the effect of NO synthase (NOS) blockers on the vasodilation induced by ␤ 1 -, ␤ 2 -, and ␤ 3 -adrenoceptors hinted that the activation of the NO/cGMP pathway may also be involved in the response to ␤-adrenoceptors (2, 8, 10, 19, 33, 35, 41) . In addition, an impaired vasodilator response to ␤-adrenoceptor agonists has been observed in cardiovascular diseases associated with endothelial dysfunction such as hypertension (6, 38) , which also suggests that an endotheliumdependent component contributes to the vasomotor signaling triggered by ␤-adrenergic activity. However, the participation of the NO/cGMP pathway in the vascular response to ␤-adrenoceptor activation remains controversial. The finding that ␤ 1 -and ␤ 2 -adrenoceptors are rapidly desensitized in isolated cells and in reconstituted receptor-G s protein preparations (22, 30, 32) but not in human forearm arteries (37) led to Whalen et al. (45) to hypothesize that NO prevents the rapid desensitization of ␤-adrenoceptors in vivo. Consequently, these authors proposed that the sensitivity of the vasodilator response elicited by ␤-adrenoceptors to the NO availability simply may reflect the indirect effect of the basal NO production on the ␤-adrenoceptors expressed in the smooth muscle cells (44, 45) .
Furthermore, although the expression of ␤ 3 -adrenoceptors has been detected in the endothelial cells of aorta (35) and human coronary resistance arteries (10) and the ␤ 3 -adrenoceptors-induced vasodilation in vitro has been ascribed to the activation of the NO/cGMP pathway (8, 10, 35, 41) , the vasomotor response to ␤ 3 -adrenergic stimuli has been reported to be resistant to or upregulated by the blockade of NOS in vivo (44) .
Because the participation of NO in the ␤-adrenoceptormediated vasodilation has been inferred using NOS blockers and the basal, tonic NO production may modulate the function of smooth muscle ␤-adrenoceptors (20, 44, 45) , it is imperative to detect directly the changes in NO release to clarify the involvement of the endothelium in the ␤-adrenergic vasodilator signaling.
In the present study, we hypothesized that the vasodilation mediated by ␤ 1 -, ␤ 2 -, and ␤ 3 -adrenoceptor activation either by epinephrine or structurally related agonists possesses an endothelium-dependent component that is linked to the activation of the endothelial NOS (eNOS). To test this hypothesis, we aimed at the following: 1) to determine the participation of the NO/cGMP pathway in the epinephrine-induced vascular re-sponse mediated by activation of ␤-adrenoceptors in the isolated arterial mesenteric bed of the rat ex vivo; 2) to evaluate the phosphorylation of eNOS in response to epinephrine or selective ␤-adrenoceptor activation; and 3) to examine in vivo the role of NO in the control of arterial blood pressure by ␤-adrenoceptors. To this end, we directly measured the production of NO and cGMP in response to epinephrine and used a battery of selective ␤-adrenoceptor agonists and antagonists to dissect the contribution of distinct ␤-adrenoceptor subtypes to the endothelial component of the vascular response to epinephrine. Our results support the notion that ␤ 1 -, ␤ 2 -, and ␤ 3 -adrenoceptors are functionally expressed in the endothelium of resistance vessels and are coupled to the initiation of the NO/cGMP signaling pathway. The NO production induced by the epinephrine stimulation of ␤ 3 -adrenoceptors is associated with eNOS phosphorylation via the phosphatidylinositol 3-kinase (PI3K)/Akt pathway activation. The present results highlight the contribution of the endothelial ␤-adrenoceptors to the well-known role of smooth muscle ␤ 2 -adrenoceptors in the control of peripheral vascular resistance and blood flow distribution.
MATERIALS AND METHODS

Animal and Drug Sources
Adult Sprague-Dawley male rats (220 -250 g) were bred and maintained in the Research Animal Facility of the Pontificia Universidad Católica de Chile. All studies were approved by the Institutional Bioethics Committee, and the experiments were conducted according to the Helsinki Declaration.
Chemicals
All chemicals of analytical grade were obtained from Merck (Darmstadt, Germany). N -nitro-L-arginine (L-NNA), saponin, acetylcholine (ACh), (Ϫ)-epinephrine, isoproterenol, pindolol, (Ϯ)-propranolol (as hydrochloride salts), salbutamol, terbutaline (as hemisulfate salts), fenoterol hydrobromide, CGP 12177 {4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimidazol-2-one)}, and pentobarbital sodium were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Arterial Mesenteric Bed Perfusion Assays
Rats were anesthetized with pentobarbital sodium (40 mg/kg ip), and the arterial mesenteric bed was perfused as described previously (5, 13) . The abdominal wall was opened, and the superior mesenteric artery was cannulated and perfused at 2 ml/min with a warmed (37°C) Krebs-Ringer buffer solution equilibrated with 95% O 2-5% CO2. The mesenteries were excised from the intestinal wall and placed in a dish kept at 37°C, and thus, the mesenteric preparation was allowed to stabilize for 20 min before the experiments were started. A pressure transducer was connected at the entrance of the superior mesenteric artery to record the perfusion pressure. Three separate groups of protocols were performed to 1) detect the luminally accessible NO, 2) determine the accumulation of tissue cGMP, or 3) assess the vasomotor response induced by ␤-adrenoceptor activation. In all experiments, a single mesentery was used for each data point.
Isolated Rings of the Rat Mesenteric Artery
The abdomen of rats anesthetized with pentobarbital sodium was opened by a midline incision. The superior mesenteric artery was isolated, removed, and cut in rings 5 mm in width. The rings were mounted on 10-ml double-jacketed bath chambers filled with a KrebsRinger buffer maintained at 37°C and equilibrated with 95% O 2-5% CO2 to record the changes in isometric tension on a Grass polygraph, as described previously by Racchi et al. (34) .
Measurements of Arterial Blood Pressure
For this set of experiments, only rats of ϳ250 g were used. The carotid artery of pentobarbital sodium anesthetized rats was isolated, cleared of connective tissue, and cannulated. The arterial carotid pressure was recorded continuously throughout the experiments on a Grass polygraph. Supplemental doses of anesthetic were administered as appropriate.
Experimental Protocols NO production. RELEASE OF NO BY ␤-ADRENOCEPTOR STIMULA-TION: TIME-COURSE AND CONCENTRATION-RESPONSE STUDIES. We assessed whether epinephrine and structurally related ␤-adrenergic agonists elicited a concentration-dependent release of luminally accessible NO. For this purpose, varying concentrations of these drugs were perfused for 1 min in concentrations ranging from 1-1,000 nM. These experiments were conducted in mesenteries that were not precontracted with phenylephrine to avoid the indirect release of NO elicited by the increase in shear stress (5) . Compounds examined included epinephrine, the ␤ 1-and ␤2-adrenoceptor agonist isoproterenol, and the ␤3-adrenergic agonist BRL 37344 (4, 39) .
BLOCKADE OF THE ␤-ADRENOCEPTOR-INDUCED NO PRODUCTION:
STUDIES WITH PROPRANOLOL AND SR 59230A. To characterize the receptor(s) involved in the NO surge elicited by the adrenergic agonists, we also used the ␤-adrenoceptor antagonists propranolol, a nonselective ␤ 1-and ␤2-adrenoceptor blocker, and SR 59230A, a selective ␤3-adrenoceptor antagonist in the rodent (27) . In a first series of experiments, we analyzed the effect of 1 M propranolol or 10 nM SR 59230A on the epinephrine-induced concentration-response curve of NO production. In a second series of experiments, we assessed the effect of these ␤-adrenoceptor antagonists on the BRL 37344-induced NO surge. In addition, we also ascertained whether the release of luminal accessible NO evoked by either 100 nM of ␤ 3-adrenoceptor agonists (SR 58611A, CGP 12177, and pindolol) or 1 nM of ␤1-and/or ␤2-adrenoceptor agonists (isoproterenol, dobutamine, salbutamol, terbutaline, and fenoterol) was reduced by 1 M propranolol or 10 nM SR 59230A. As a control, separate sets of mesenteries were perfused with either 1 M propranolol or 10 nM SR 59230A alone.
ENDOTHELIUM REMOVAL AND BLOCKADE OF NO SYNTHASE. To evaluate the role of the endothelial cells in the rise of luminal NO elicited by 1 nM epinephrine, experiments were performed before and 30 min after treatment with 0.1% saponin for 55 s. This procedure has been reported to remove a substantial portion of the endothelium without damaging the adjacent vascular smooth muscle cells (5, 13) . In addition, we treated the mesenteries for 30 min with 100 M L-NNA to evaluate the enzymatic origin of the luminal NO released by stimulation with 1 nM epinephrine or 100 nM BRL 37344.
cGMP production. TISSUE cGMP ACCUMULATION. To examine whether the burst of luminal NO production was associated with a rise in its second messenger, cGMP, the experiments were performed after treatment for 20 min with 0.5 mM IBMX, a nonselective phosphodiesterase inhibitor (40) . Thus mesenteries were perfused with epinephrine or a series of ␤-adrenergic selective agonists for 1 min and rapidly homogenized. The basal tissue cGMP content was determined in mesenteries perfused with regular buffer solution. Separate groups of four to six rats were used per drug concentration examined. 
Systolic Blood Pressure
Changes in systolic blood pressure of anesthetized rats. To confirm that the outburst of NO elicited by ␤-adrenergic agonists was relevant for the control of peripheral vascular resistance and, then, systemic blood pressure, we monitored continually carotid blood pressure from pentobarbital sodium (40 mg/kg) anesthetized rats. ␤-Adrenergic agonists examined included isoproterenol, salbutamol, BRL 37344, and CGP 12177. Drugs were administered as an intravenous bolus (ranging from 0.04 to 400 g/kg) dissolved in sterile saline solution.
Once the concentration-response curve was performed, the same protocol was repeated after 30 min of slow (250 l/30 s) intravenous administration of 30 mg/kg L-NNA (24) . At the beginning of the experiments, all animals were challenged with an intravenous bolus of 4 g/kg ACh to ensure that cannulas were in place and the blood pressure monitoring system was operating correctly.
eNOS Phosphorylation
Activation of PI3K/Akt pathway and eNOS in the rat arterial mesenteric bed. To study the mechanisms involved in eNOS activation, we homogenized the mesenteries after 1 min stimulation with 1 nM epinephrine, 100 nM BRL 37344, or 100 nM isoproterenol to analyze simultaneously the phosphorylation of Akt in serine 473 (P-Akt S473 ) and eNOS in serine 1177 (P-eNOS S1177 ).
Analytical Techniques
Quantification of NO release by chemiluminiscence. To measure the luminally accessible NO release, perfusate samples were collected once every minute and the content of NO was quantified using a Sievers 280 NO analyzer, as detailed by Boric et al. (5) . In essence, the nitrites from each sample were reduced to NO in a reaction chamber containing 80 mM KI. A stream of N 2 carried the resulting NO to a cell in which the chemiluminiscence generated by NO-O3 reaction was quantified. Equipment calibration was performed with 10 -1,000 nM sodium nitrite. The NO detection limit was 0.5-1 pmol (10 -20 pmol/ml). Background readings were subtracted to determine the net release. Results were expressed either as the time course (pmol/min) or as the total NO released above basal values (pmol).
cGMP quantification by RIA. Total tissue nucleotide accumulation was determined as described previously (5, 13) . Tissues were homogenized in 10% trichloroacetic acid and centrifuged at 4°C for 30 min at 1,900 g. The aqueous phase was extracted four times with four volumes of ethyl ether each run. The samples were dried using a speed vac and stored at Ϫ20°C for Ͻ2 wk until the RIA for cGMP was performed. Results were expressed as the tissue cGMP (pmol/g tissue) production induced by the agonist.
Western blotting. Protein samples (80 g, Bradford method) were separated by 8% SDS-PAGE and transferred onto a nitrocellulose membrane (Bio-Rad, Hercules, CA). The membrane was incubated with a primary antibody overnight at 4°C and then with the appropriate secondary antibody (2 h at room temperature). The protein bands were detected using SuperSignal West Femto (Pierce, Rockford, IL). Molecular mass was estimated with prestained markers (Bio-Rad). The same membrane was first developed for P-Akt S473 or P-eNOS S1177 , and, then, for total protein after stripping. The primary antibodies (monoclonal anti-eNOS, monoclonal anti-P-eNOS S1177 , monoclonal anti-Akt, and monoclonal anti-P-Akt S473 ) were purchased from BD-Transduction Labs (Lexington, KY). Western blots were submitted to densitometric analysis using National Institutes of Health-image software, and changes in the degree of Akt or eNOS phosphorylation are expressed as the ratio of phosphorylated protein over total protein.
Statistical analysis and quantification of results. One-way ANOVA plus Newman Keuls post hoc test, Student's t-test, or Dunnett's tables for multiple comparisons with a single control were used when appropriate. Concentration-response curves were fitted using GraphPad software (San Diego, CA); the median effective concentration (EC 50), and the maximal efficacy (Emax) were calculated from the curves. The level of significance was set at P Ͻ 0.05.
RESULTS
Epinephrine Induces an Endothelium-Dependent Rise in Luminal NO
Perfusion of the rat arterial mesenteric bed for 1 min with 1 nM epinephrine elicited a transient rise in luminal accessible NO. The surge of NO subsided within 2-3 min, reaching the same basal levels observed before the epinephrine application (Fig. 1A) . The total net increase in NO production (341.3 Ϯ 29.1 pmol; n ϭ 12) was drastically reduced by NOS blockade with 100 M L-NNA or endothelium removal by treatment with saponin (Fig. 1B) , indicating that epinephrine triggered the activation of eNOS.
Rise in Luminal NO Was Coupled to cGMP Production
As shown in Fig. 1C , a 1-min stimulation with 1 nM epinephrine resulted in an increase in the tissue cGMP content that was obliterated by treatment with L-NNA or saponin. Interestingly, both NOS blockade or endothelium removal also reduced the basal tissue content of cGMP from 97.7 Ϯ 7.6 pmol/g (n ϭ 7) to 33.8 Ϯ 3.1 pmol/g (n ϭ 4) and to 33.2 Ϯ 5.7 pmol/g (n ϭ 4), respectively (P Ͻ 0.001, by one-way ANOVA). These results confirm that endothelial NO is the main stimulus for basal and epinephrine-induced cGMP production in this preparation and discard the participation of the adipose tissue in the response to epinephrine. We used 1 M ACh as an internal control for the RIA, which consistently induced a L-NNA-sensitive increase in cGMP (control: 644.9 Ϯ 63.1 pmol/g, n ϭ 5, and L-NNA treatment: 22.4 Ϯ 6.5 pmol/g, n ϭ 4; P Ͻ 0.05).
Multiple ␤-Adrenoceptors Are Involved in the Epinephrine-Evoked Rise in Luminal NO
The rise in luminal NO induced by epinephrine was concentration dependent ( Fig. 2A) with a median effective concentration of 45.7 pM and a maximal effect of 395.2 Ϯ 50.3 pmol of NO (Table 1 ). Both 10 nM SR 59230A or 1 M propranolol displaced in a parallel manner the epinephrine concentrationresponse curve ϳ10-fold to the right ( Fig. 2A) , as expected for a competitive antagonist. Moreover, although 1 M propranolol only decreased by ϳ50% the epinephrine-induced luminal NO surge, the joint application of 10 nM SR 59230A plus 1 M propranolol obliterated the epinephrine-induced NO production ( Fig. 2A) , indicating the likely involvement of the ␤ 1 -, ␤ 2 -, and ␤ 3 -adrenoceptors in the response to epinephrine. As a control, application of 100 nM SR 59230A or 1 M propran-olol per se did not produce a significant increase in basal NO release (14.9 Ϯ 8.9 pmol, n ϭ 4, and 13.7 Ϯ 7.8 pmol, n ϭ 4, respectively).
The participation of ␤-adrenoceptors in the epinephrineinduced NO production was further confirmed by direct stimulation of ␤ 1 -and ␤ 2 -adrenoceptors with isoproterenol or ␤ 3 -adrenoceptors with BRL 37344. Both ␤-adrenoceptor agonists, isoproterenol and BRL 37344, evoked a concentrationdependent NO release ( Fig. 2B; Table 1 ) consistent with the magnitude of the inhibition observed in the response to epinephrine in presence of propranolol and SR 59230A.
Furthermore, the rise in luminal NO induced by 1 nM isoproterenol, terbutaline, salbutamol, or fenoterol was blunted by 1 M propranolol (Fig. 3A) , indicating that the NO production elicited by these agonists is mediated by ␤ 1 -and/or ␤ 2 -adrenoceptors activation. However, the rise in luminal NO evoked by dobutamine was only partially blocked by propranolol (Fig. 3A) , which suggests that this agonist might activate other adrenoceptors in addition to ␤ 1 or ␤ 2 . In contrast, the rise in NO elicited by 100 nM BRL 37344 was not blocked by 1 Values of EC50 are means Ϯ 95% confidence intervals. Values of maximal nitric oxide production (Emax) are means Ϯ SE.
M propranolol (Fig. 3A) , confirming the ␤ 3 -adrenoceptor selectivity of this agonist. Consistent with the activation of eNOS by ␤ 3 -adrenoceptor, the rise in luminal NO elicited by 100 nM of CGP 12177, SR 58611A, or pindolol was significantly reduced by 10 nM SR 59230A (Fig. 3B) . The relative potency of all these agonists and their maximal efficacy to stimulate NO production are summarized in Table 1 .
Consonant with the previous findings, the BRL 37344 concentration-response curve was displaced to the right in a parallel manner by 10 nM SR 59230A but not by 1 M propranolol (Fig. 3C) . Moreover, the joint application of SR 59230A plus propranolol did not further displace the BRL 37344 concentration-response curve (Fig. 3C) , which demonstrates that the effect of BRL 37344 is resistant to propranolol.
As expected, stimulation with 1 nM isoproterenol, dobutamine, or salbutamol resulted in an accumulation of cGMP content in the arterial mesenteric bed (Table 2 ). Likewise, a 1-min perfusion of 100 nM BRL 37344, pindolol, or CGP 12177 also increased the cGMP in the mesentery (Table 2) . These results, therefore, indicate that activation of all three ␤-adrenoceptors is coupled to the stimulation of cGMP production by the arterial mesenteric bed, which is consistent with the rise in NO release induced by epinephrine and the ␤ 1 -, ␤ 2 -, and ␤ 3 -adrenoceptor agonists.
Vasomotor Effect of Endothelial ␤ 3 -Adrenoceptors
Basal NO production may regulate the activity of ␤ 1 -and ␤ 2 -adrenoceptors in the smooth muscle cells (45) , which may lead to misinterpretation of the magnitude of the endotheliumdependent vasodilator component activated by these adrenoceptors. Then, we focused on the participation of ␤ 3 -adrenoceptors in the control of vasomotor tone. As expected, perfusion with 1 M BRL 37344 resulted in relaxation of the arterial mesenteric network, which was abolished by 10 nM SR 59230A (Fig. 4A) .
To carry out a more detailed study of the vasodilator effect observed in response to the activation of ␤ 3 -adrenoceptors, we used isolated rings of the mesenteric superior artery. Consistent with the activation of the NO/cGMP pathway by ␤ 3 -adrenoceptor ( Figs. 2 and 3 ; Table 2 ), stimulation with BRL 37344 induced a concentration-related vasorelaxation in an endothelium-dependent manner (Fig. 4B ) that was completely coherent with the L-NNA-sensitive NO production observed in the arterial mesenteric bed in response to this ␤ 3 -adrenoceptor agonist (Fig. 4C) . The endothelium removal in these preparations was verified by the severe reduction in the relaxation induced by the endothelium-dependent vasodilator ACh (100 nM) from 80 Ϯ 10 to 15 Ϯ 5.5% (n ϭ 8 -12; P Ͻ 0.05).
Arterial Blood Pressure in Anesthetized Rats
We next examined whether the activation of the NO/cGMP pathway by ␤-adrenoceptors participates in the control of peripheral vascular resistance. Administration of an intrave- nous bolus of ␤-adrenoceptor agonists elicited a rapid, shortlived dose-dependent decrease in systolic blood pressure (data not shown). The response in blood pressure elicited by intravenous administration of ␤-adrenoceptor agonists was significantly reduced in rats pretreated with L-NNA (Fig. 5) . Treatment with L-NNA produced a progressive increase in blood pressure, reaching a stable level within 20 -30 min; the rise in systolic blood pressure amounted to 70.5 Ϯ 7.1 mmHg (n ϭ 33). Although the L-NNA treatment did not change the amplitude of the decrease in systolic blood pressure induced by isoproterenol or salbutamol (Fig. 5, A and B) , the duration of the responses to these ␤-adrenoceptor agonists was consistently shorter (Fig. 5, A and C) , as was observed with the blood pressure response to ACh in presence of L-NNA (data not shown). In contrast, the vasodepressor response to BRL 37344 was reduced by L-NNA treatment in both amplitude and duration (Fig. 5, A-C) . Altogether, these findings reveal the participation of NO production in the vasodepressor response induced by the activation of ␤ 1 -, ␤ 2 -, and ␤ 3 -adrenoceptors.
Epinephrine Induces eNOS Phosphorylation by ␤ 3 -Adrenoceptor Activation
To explore the mechanisms of eNOS activation by epinephrine, we analyzed the phosphorylation of eNOS in serine 1177 via the PI3K/Akt pathway in the arterial mes- enteric bed. The participation of the PI3K/Akt pathway was evaluated by checking the phosphorylation of Akt in serine 473. In control conditions, the signal of both phospho-Akt and phospho-eNOS was clearly detected. Interestingly, stimulation with 1 nM epinephrine for 1 min resulted in an increase in P-Akt S473 as well as in P-eNOS S1177 without changes in the amount of protein (Fig. 6A) , which suggests that the NO production induced by this hormone is initiated, at least in part, through eNOS phosphorylation via the activation of the PI3K/Akt pathway. A similar increase in phospho-Akt and phospho-eNOS was induced by the stimulation with BRL 37344 (Fig. 6B) . However, isoproterenol did not change the degree of Akt and eNOS phosphorylation (Fig. 6C) , which indicates that the ␤-adrenoceptors activated by epinephrine in the endothelial cells are coupled to NO production through the activation of different signaling pathways.
DISCUSSION
The present results demonstrate that epinephrine activates the NO/cGMP vasodilator pathway in resistance vessels via the stimulation of ␤ 1 -, ␤ 2 -, and ␤ 3 -adrenoceptors. The response to epinephrine or selective ␤-adrenoceptor agonists was abolished by blockade of NOS or removal of the endothelium. In addition, epinephrine or selective ␤ 3 -adrenoceptor stimulation evoked the phosphorylation of eNOS through the activation of the PI3K/Akt pathway, which provides new insights in the understanding of the epinephrine-initiated ␤-adrenergic transduction pathways leading to eNOS activation in the endothelial cells. These results, therefore, highlight the role of the endothelium in the control of vasomotor tone and blood flow distribution by epinephrine.
The arterial mesenteric bed is a vascular resistance territory suited to evaluate the activation of ␤-adrenoceptor by epinephrine (44 -46) in which we can measure minute-to-minute NO production, eNOS phosphorylation, and tissue accumulation of cGMP (5) . Furthermore, as we have shown previously (5, 13) , it is possible to remove the endothelial cell layer of this vascular bed without damaging the smooth muscle cells by perfusing a mild detergent. This preparation, therefore, enabled us to study the endothelium-or smooth muscle-dependent vasomotor signaling triggered by adrenoceptor stimulation and to directly assess the participation of eNOS in the response. The present findings in the rat arterial mesenteric bed combined with the arterial blood pressure measurements in the anesthetized rats provide complementary information linking unambiguously the ␤-adrenoceptor activity to the NO/cGMP signaling pathway in a physiological context.
Several lines of evidence support the functional expression of multiple endothelial ␤-adrenoceptors linked to the activation of eNOS. First, epinephrine and all the selective ␤-adrenoceptor agonists tested in this study induced NO production, a response that was blocked by L-NNA or endothelium removal. The response to epinephrine was also inhibited by the ␤ 1 -/␤ 2 -adrenoceptor antagonist propranolol and the ␤ 3 -adrenoceptor antagonist SR 59230A. Second, propranolol blocked the dobutamine-induced NO release, indicating the involvement of ␤ 1 -adrenoceptors. Third, propranolol blunted the response elicited by either ␤ 1 -or ␤ 2 -adrenoceptor agonists such as isoproterenol, terbutaline, salbutamol, or fenoterol but not that to the ␤ 3 -adrenoceptor agonist BRL 37344, which supports that ␤ 2 -adrenoceptors are involved in the response as well. Fourth, the BRL 37344-induced NO production, vasodilation, and reduction in systolic blood pressure were blocked by SR 59230A, establishing the selectivity of this agonist for ␤ 3 -adrenoceptors. SR 59230A also blocked the activity of other ␤ 3 -adrenoceptorselective agonists including CGP 12177, SR 58611A, and pindolol. Finally, epinephrine and BRL 37344 evoked the phosphorylation of eNOS. Taken together, these findings add strong pharmacological evidence in favor of the hypothesis that ␤ 1 -, ␤ 2 -, and ␤ 3 -adrenoceptors are functionally expressed in the endothelial cells and are coupled to the activation of the NO/cGMP vasodilator pathway.
Although ␤ 1 -and ␤ 2 -adrenoceptors are coupled to the NO/ cGMP pathway, the L-NNA treatment only affected the duration of the vasodepressor response induced by isoproterenol or salbutamol. The release of an endothelium-derived hyperpolarizing factor that has been typically observed in the response to ACh (42) has also been involved in the response to ␤ 1 -and ␤ 2 -adrenoceptors (12) . The endothelium-derived hyperpolarizing factor may compensate for the reduced bioavailability of NO (7, 28) . Therefore, the upregulation of this endothelial factor may explain the lack of effect of the L-NNA treatment on the peak decrease of systolic blood pressure induced by isoproterenol, salbutamol, or ACh, which is consistent with the finding that NOS inhibition attenuates the duration, but not the magnitude, of the ACh-induced vasodilation observed in resistance vessels (36) . Alternatively, the activation of ␤-adrenoceptors in the heart may have masked the peak in the reduction of systolic blood pressure induced by isoproterenol and salbutamol.
A noteworthy contribution of our proposal is the recognition that the role of epinephrine as a blood flow regulator relies on the activation of different mechanisms depending on the smooth muscle and the endothelial cells. The present data indicate that, in addition to the classical activation of the vascular smooth muscle ␤ 2 -adrenoceptor, epinephrine acts on endothelial ␤ 1 -, ␤ 2 -, and ␤ 3 -adrenoceptors, all of which contribute to induce a NO-dependent vasodilation. The finding that epinephrine acts on several endothelial ␤-adrenoceptors coupled to different signaling pathways may account for its extraordinary potency and efficacy to produce NO compared with selective ␤-adrenoceptor agonists. The endothelial localization of multiple ␤-adrenoceptors offers a more integrative explanation for the role of epinephrine in the control of arterial blood pressure and blood flow distribution. In this context, the endothelial cells are the first target for the vascular action of epinephrine, since the activation of smooth muscle adrenoceptors will be dependent on the rate of diffusion of the hormone through the endothelium. This notion is particularly relevant in arterioles, where the endothelial barrier shows low permeability to hydrophilic molecules (26) , which may regulate the balance of the vasomotor activity of epinephrine in the endothelial and smooth muscle cells. On the other hand, the release of the cotransmitters ATP and norepinephrine by peripheral sympathetic stimulation at the adventitial side of the vessel will favor vasoconstriction through the activation of purinergic P2X and ␣-adrenoceptors in the smooth muscle cells over the vasodilation in response to ␤-adrenoceptors located on the endothelial cells. Therefore, the vascular tone is modulated by interplay between multiple ␣-and ␤-adrenoceptors acting on the endothelium and the vascular smooth muscle. This view may account for the observation that intravenous bolus injections of epinephrine (0.01-0.1 mg/kg) to humans or anesthetized experimental animals typically elicit vasodilation (43) . The preferential activation of endothelial ␤-adrenoceptors by epinephrine provides an additional mechanism to explain the role played by this hormone in the blood flow redistribution, such as in the skeletal muscle during the exercise. However, it is important to note that intravenous injections of norepinephrine result in an increase in peripheral vascular resistance, which may be attributed to the low affinity of this sympathetic cotransmitter for the ␤ 2 -adrenoceptors.
Although the ␤ 3 -adrenoceptor was cloned from adipose tissue almost 20 years ago, its role in cardiovascular physiology began to be appreciated only within the past 10 yr by Gauthier et al. (16 -18) , who described the negative inotropic effect of these adrenoceptors in humans. In blood vessels, ␤ 3 -adrenoceptors have been detected only in the endothelial cells (10, 35) and our results indicate that they are coupled to NO production through the activation of the PI3K/Akt pathway and eNOS phosphorylation in serine 1177, a well-known mechanism of eNOS activation (14, 15) . Interestingly, in contrast to ␤ 1 -and ␤ 2 -adrenoceptors, ␤ 3 -adrenoceptors are not desensitized by phosphorylation. Because it has been proposed that NO availability prevents the phosphorylation-dependent desensitization of ␤ 1 -and ␤ 2 -adrenoceptors (44, 45), we hypothesize that the NO production mediated by endothelial ␤ 3 -adrenoceptor activation may recruit desensitized ␤ 1 -and ␤ 2 -adrenoceptors during the vasomotor response to chronic epinephrine secretion such as in prolonged stressful conditions. Thereby, the ␤ 3 -adrenoceptors may play a role coordinating and integrating the endothelial ␤-adrenergic response to epinephrine.
The present results corroborate that the intrinsic sympathomimetic activity of certain ␤-adrenoceptor drugs observed in human clinics might be related to the interplay of multiple ␤-adrenoceptors (1, 11, 21) . It is known that some ␤ 1 -and ␤ 2 -adrenergic antagonists such as pindolol act as ␤ 3 -adrenoceptor agonists (4, 39) . Consistent with this idea, the present results show that, in the rat arterial mesenteric bed, the potency of pindolol and BRL 37344 is within the same order of magnitude. These findings reveal the complex pharmacology of this drug, which is also a 5-HT 1A/1B receptor antagonist (9) . It is interesting to note that we corroborated that propranolol lacks ␤ 3 -adrenergic activity, although this drug and pindolol are structurally related analogs. Moreover, our results indicate that CGP 12177 is a partial ␤ 3 -adrenoceptor agonist as noticed by Strosberg (39) . In light of the relative subtype selectivity of the adrenergic drugs, it has not escaped our attention that the NO production elicited by dobutamine, an alleged selective ␤ 1 -adrenoceptor agonist, was only partially blocked by 1 M propranolol, which suggests that dobutamine might also activate ␤ 3 -adrenoceptors. In addition, although SR 59230A seems to be a selective ␤ 3 -adrenoceptor antagonist in rats, its activity in humans has been questioned (3). Therefore, these results highlight the complex pharmacology of ␤-adrenoceptors, which imposes the requirement to duly control the pharmacological activity of these drugs.
In summary, the modulation of vascular resistance elicited by sympatho-adrenal stimulation or by therapeutically relevant adrenergic agonists involves the coordinated response of the endothelial and smooth muscle cells through the activation of multiple ␣-and ␤-adrenoceptor subtypes. Our results demonstrate that epinephrine is coupled to endothelium-dependent NO production through the stimulation of ␤ 1 -, ␤ 2 -, and ␤ 3 -adrenoceptors. While the ␤ 3 -adrenoceptor-induced NO release is mediated by activation of the PI3K/Akt pathway and eNOS phosphorylation in serine 1177, the transduction mechanisms involved in the NO production initiated by ␤ 1 -and ␤ 2 -adrenoceptors remain to be determined. These findings offer new insights for the role of endothelial cells in cardiovascular diseases in which the response to epinephrine is altered, as the excessive increases in arterial blood pressure produced by exercise in hypertension (23, 25, 31, 38) . Then, endothelial ␤-adrenoceptors are potential targets for the design of new therapeutic strategies to improve the vascular function. Although it is necessary to be cautious in extrapolating the pharmacological properties of ␤ 3 -adrenergic drugs from rodents to humans (3), the finding that the vasodilator response to BRL 37344 in human coronary microarteries is blocked by bupranolol, a nonselective ␤ 1 -, ␤ 2 -and ␤ 3 -adrenoceptor antagonist, is encouraging (10) . It is likely that the expression of multiple ␤-adrenoceptors is not redundant and the cross-talk between the signaling mechanisms of these adrenoceptors may play a central role integrating the vascular response to catecholamines.
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